{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:25:56Z","timestamp":1788193556852,"version":"build-2803163510"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"R\u00edo Hortega Fellowship","award":["CM21\/00178"],"award-info":[{"award-number":["CM21\/00178"]}]},{"name":"R\u00edo Hortega Fellowship","award":["PMP22\/00158"],"award-info":[{"award-number":["PMP22\/00158"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate clinical characteristics, effectiveness, and tolerability of preventive anti- calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) in the elderly. Anti-CGRP mAbs have demonstrated efficacy and safety in patients with migraine although there is limited information regarding the elderly.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>We performed a multicenter case-control study of cases (patients over 65\u2009years old) and controls (sex-matched patients under 55\u2009years old) with migraine receiving anti-CGRP mAbs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We included the demographic characteristics, effectiveness\u2014reduction in the number of monthly headache days (MHD) and monthly migraine days (MMD), 30%, 50%, and 75% responder rates\u2014and treatment emergent adverse events (TEAEs). The primary endpoint was the 50% response rate regarding MHD at weeks 20\u201324; exploratory 50% response predictors in the elderly were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 228 patients were included: 114 cases , 114 controls-. Among cases 84.2% (96\/114) were women, 79.8% (91\/114) CM; mean age of cases 70.1\u2009years old (range: 66\u201386); mean age of controls was 42.9\u2009years old(range: 38\u201349). Cases had a higher percentage of vascular risk factors (P\u2009&amp;lt;\u2009.05),older age of onset (P\u2009&amp;lt;\u2009.001) and more reported prior preventive treatments (P\u2009&amp;lt;\u2009.001). Regarding effectiveness in cases, 50% response rate was achieved by 57.5% (42\/73) at 20\u201324\u2009weeks, with lower reduction in the MHD at 8\u201312\u2009weeks (5 [7.2], 8 [9.1]; P\u2009=\u2009.001) and a higher reduction in MMD at 20\u201324\u2009weeks (10.7 [9.1], 9.2 [7.7]; P\u2009=\u2009.04) compared to the control group. The percentage of TEAEs was similar in the 2 groups. Diagnosis of episodic migraine (EM) (P\u2009=\u2009.03) and lower number of MHD at baseline (P\u2009= .001) were associated with a 50% response in the elderly in univariate analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study provides real world evidence of effectiveness and safety of anti-CGRP mAbs for migraine in patients without upper age-limit and possible predictors of anti-CGRP response in the elderly.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/pm\/pnad141","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T16:25:16Z","timestamp":1697559916000},"page":"194-202","source":"Crossref","is-referenced-by-count":11,"title":["Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1228-1503","authenticated-orcid":false,"given":"Alicia","family":"Gonzalez-Martinez","sequence":"first","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Universitario de la Princesa , Madrid, Madrid 28006,","place":["Spain"]},{"name":"Department of Medicine, Universidad Aut\u00f3noma de Madrid , Madrid, Madrid 28049,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-5108","authenticated-orcid":false,"given":"Ancor","family":"Sanz-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Data Analysis Unit, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Hospital Universitario de la Princesa , Madrid, Madrid 28006,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-1064","authenticated-orcid":false,"given":"David","family":"Garc\u00eda-Azor\u00edn","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Cl\u00ednico Universitario de Valladolid , Valladolid, Castilla y Le\u00f3n 47003,","place":["Spain"]},{"name":"Department of Medicine, University of Valladolid , Valladolid, Castilla y Le\u00f3n 47003,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Rodr\u00edguez-Vico","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz , Madrid, Madrid 28040,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Jaimes","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz , Madrid, Madrid 28040,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"G\u00f3mez Garc\u00eda","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz , Madrid, Madrid 28040,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Casas-Lim\u00f3n","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n , Alcorc\u00f3n, Madrid 28922,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"D\u00edaz de Ter\u00e1n","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Universitario La Paz , Madrid, Madrid 28046,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Sastre-Real","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Universitario La Paz , Madrid, Madrid 28046,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Membrilla","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Universitario La Paz , Madrid, Madrid 28046,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germ\u00e1n","family":"Latorre","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Universitario de Fuenlabrada , Madrid, Madrid 28942,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Calle de Miguel","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Universitario de Fuenlabrada , Madrid, Madrid 28942,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sendoa","family":"Gil Luque","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Universitario de Burgos , Burgos, Castilla y Le\u00f3n 09006,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8711-4884","authenticated-orcid":false,"given":"Cristina","family":"Trevino-Peinado","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Universitario Severo Ochoa , Legan\u00e9s, Madrid 28914,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0622-8228","authenticated-orcid":false,"given":"Sonia","family":"Quintas","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Universitario de la Princesa , Madrid, Madrid 28006,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Heredia","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Universitario de la Princesa , Madrid, Madrid 28006,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7038-2911","authenticated-orcid":false,"given":"Ana","family":"Echavarr\u00eda-\u00cd\u00f1iguez","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Cl\u00ednico Universitario de Valladolid , Valladolid, Castilla y Le\u00f3n 47003,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7493-6002","authenticated-orcid":false,"given":"\u00c1ngel","family":"Guerrero-Peral","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Cl\u00ednico Universitario de Valladolid , Valladolid, Castilla y Le\u00f3n 47003,","place":["Spain"]},{"name":"Department of Medicine, University of Valladolid , Valladolid, Castilla y Le\u00f3n 47003,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0022-6064","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Sierra","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Cl\u00ednico Universitario de Valladolid , Valladolid, Castilla y Le\u00f3n 47003,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8630-3384","authenticated-orcid":false,"given":"Nuria","family":"Gonz\u00e1lez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Cl\u00ednico San Carlos , Madrid, Madrid 28040,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7034-682X","authenticated-orcid":false,"given":"Jes\u00fas","family":"Porta-Etessam","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Cl\u00ednico San Carlos , Madrid, Madrid 28040,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0038-3406","authenticated-orcid":false,"given":"Ana Beatriz","family":"Gago-Veiga","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Hospital Universitario de la Princesa , Madrid, Madrid 28006,","place":["Spain"]},{"name":"Department of Medicine, Universidad Aut\u00f3noma de Madrid , Madrid, Madrid 28049,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"issue":"6","key":"2025082211565591800_pnad141-B1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"issue":"24","key":"2025082211565591800_pnad141-B2","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"issue":"22","key":"2025082211565591800_pnad141-B3","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2025082211565591800_pnad141-B4","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"issue":"8","key":"2025082211565591800_pnad141-B5","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"issue":"19","key":"2025082211565591800_pnad141-B6","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"issue":"10","key":"2025082211565591800_pnad141-B7","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1007\/s00415-021-10523-8","article-title":"The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study","volume":"268","author":"Torres-Ferr\u00fas","year":"2021","journal-title":"J Neurol"},{"issue":"2","key":"2025082211565591800_pnad141-B8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/head.14032","article-title":"Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study","volume":"61","author":"Barbanti","year":"2021","journal-title":"Headache"},{"issue":"1","key":"2025082211565591800_pnad141-B9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","article-title":"Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)","volume":"22","author":"Vernieri","year":"2021","journal-title":"J Headache Pain"},{"issue":"6","key":"2025082211565591800_pnad141-B10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/pmt-2021-0015","article-title":"PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine","volume":"11","author":"Ashina","year":"2021","journal-title":"Pain Manag"},{"issue":"3","key":"2025082211565591800_pnad141-B11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.anclin.2019.04.007","article-title":"Geriatric pharmacology: an update","volume":"37","author":"Andres","year":"2019","journal-title":"Anesthesiol Clin"},{"issue":"7","key":"2025082211565591800_pnad141-B12","first-page":"700","article-title":"Monoclonal antibodies targeting CGRP: from clinical studies to real-world evidence-what do we know so far?","volume":"14","author":"Mavridis","year":"2021","journal-title":"Pharm Basel Switz"},{"issue":"4","key":"2025082211565591800_pnad141-B13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","article-title":"Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"15","author":"Sun","year":"2016","journal-title":"Lancet Neurol"},{"issue":"10161","key":"2025082211565591800_pnad141-B14","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet"},{"key":"2025082211565591800_pnad141-B15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40695-020-00059-8","article-title":"The impact of midlife on migraine in women: summary of current views","volume":"6","author":"Pavlovi\u0107","year":"2020","journal-title":"Womens Midlife Health"},{"issue":"5","key":"2025082211565591800_pnad141-B16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2165\/00002512-199813050-00003","article-title":"Drug dosage in the elderly. Is it rational?","volume":"13","author":"Turnheim","year":"1998","journal-title":"Drugs Aging"},{"key":"2025082211565591800_pnad141-B17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/bs.irn.2022.07.003","article-title":"Sex and age differences in migraine treatment and management strategies","volume":"164","author":"Lebedeva","year":"2022","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"2025082211565591800_pnad141-B18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s10194-022-01423-x","article-title":"Efficacy and safety of fremanezumab in clinical trial participants aged \u226560\u2009years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies","volume":"23","author":"Nahas","year":"2022","journal-title":"J Headache Pain"},{"issue":"10","key":"2025082211565591800_pnad141-B19","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol"},{"key":"2025082211565591800_pnad141-B20","author":"Sociedad Espa\u00f1ola de Neurolog\u00eda","year":"2020"},{"issue":"4","key":"2025082211565591800_pnad141-B21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"Von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2025082211565591800_pnad141-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"issue":"13","key":"2025082211565591800_pnad141-B23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0025-7753(02)72429-9","article-title":"Validation of the Spanish versions of the Montgomery-Asberg Depression Rating Scale and the Hamilton Anxiety Rating Scale for the assessment of depression and anxiety","volume":"118","author":"Lobo","year":"2002","journal-title":"Med Clin (Barc)"},{"issue":"12","key":"2025082211565591800_pnad141-B24","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jclinepi.2004.05.004","article-title":"The Short-Form Headache Impact Test (HIT-6) was psychometrically equivalent in nine languages","volume":"57","author":"Martin","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"2025082211565591800_pnad141-B25","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/0333102418758283","article-title":"Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults","volume":"38","author":"Tassorelli","year":"2018","journal-title":"Cephalalgia"},{"issue":"10","key":"2025082211565591800_pnad141-B26","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102420941839","article-title":"Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults","volume":"40","author":"Diener","year":"2020","journal-title":"Cephalalgia"},{"issue":"20","key":"2025082211565591800_pnad141-B27","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"2025082211565591800_pnad141-B28","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1111\/head.13414","article-title":"Recommendations on the use of anti-CGRP monoclonal antibodies in children and adolescents","volume":"58","author":"Szperka","year":"2018","journal-title":"Headache J Head Face Pain"},{"issue":"9","key":"2025082211565591800_pnad141-B29","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1007\/s10072-022-06190-w","article-title":"Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study","volume":"43","author":"Cetta","year":"2022","journal-title":"Neurol Sci"},{"key":"2025082211565591800_pnad141-B30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-030-33330-0_4","article-title":"Epidemiology of cardiovascular diseases in the elderly","volume":"1216","author":"Noale","year":"2020","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"2025082211565591800_pnad141-B31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/ggi.12061","article-title":"Migraine and vascular risk factors in the elderly","volume":"14","author":"Gilad","year":"2014","journal-title":"Geriatr Gerontol Int"},{"issue":"1","key":"2025082211565591800_pnad141-B32","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/head.14051","article-title":"Hypertension: a new safety risk for patients treated with erenumab","volume":"61","author":"Saely","year":"2021","journal-title":"Headache"},{"issue":"6","key":"2025082211565591800_pnad141-B33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1055\/s-0037-1607393","article-title":"Migraine in women","volume":"37","author":"Broner","year":"2017","journal-title":"Semin Neurol"},{"issue":"1","key":"2025082211565591800_pnad141-B34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","article-title":"Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6\u2009months","volume":"22","author":"Caronna","year":"2021","journal-title":"J Headache Pain"},{"issue":"10","key":"2025082211565591800_pnad141-B35","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1111\/ene.15458","article-title":"Machine-learning-based approach for predicting response to anti-calcitonin gene-related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: a multicenter Spanish study","volume":"29","author":"Gonzalez-Martinez","year":"2022","journal-title":"Eur J Neurol"},{"issue":"6","key":"2025082211565591800_pnad141-B36","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cpdd.345","article-title":"Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date","volume":"6","author":"Pellesi","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"2025082211565591800_pnad141-B37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s10194-021-01279-7","article-title":"Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6\u2009months of treatment in the phase 3b FOCUS study","volume":"22","author":"Ashina","year":"2021","journal-title":"J Headache Pain"},{"issue":"9406","key":"2025082211565591800_pnad141-B38","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0140-6736(04)15440-8","article-title":"Migraine","volume":"363","author":"Silberstein","year":"2004","journal-title":"Lancet"},{"key":"2025082211565591800_pnad141-B39","doi-asserted-by":"crossref","first-page":"106893","DOI":"10.1016\/j.clineuro.2021.106893","article-title":"Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis","volume":"209","author":"Soni","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"issue":"10","key":"2025082211565591800_pnad141-B40","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1111\/head.13968","article-title":"Erenumab in chronic migraine: an Australian experience","volume":"60","author":"Cheng","year":"2020","journal-title":"Headache"},{"issue":"9","key":"2025082211565591800_pnad141-B41","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/head.13951","article-title":"Real-world patient experience with erenumab for the preventive treatment of migraine","volume":"60","author":"Robblee","year":"2020","journal-title":"Headache"},{"issue":"7","key":"2025082211565591800_pnad141-B42","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1526-4610.2006.00444.x","article-title":"Migraine changes with age: IMPACT on migraine classification","volume":"46","author":"Kelman","year":"2006","journal-title":"Headache"},{"issue":"2","key":"2025082211565591800_pnad141-B43","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1212\/01.wnl.0000225186.76323.69","article-title":"Age-dependent prevalence and clinical features of migraine","volume":"67","author":"Bigal","year":"2006","journal-title":"Neurology"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/painmedicine\/advance-article-pdf\/doi\/10.1093\/pm\/pnad141\/53433574\/pnad141.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/25\/3\/194\/56813673\/pnad141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/25\/3\/194\/56813673\/pnad141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T15:57:09Z","timestamp":1755878229000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/25\/3\/194\/7320018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,10,17]]},"published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnad141","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2023,10,17]]}}}